Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN versus M ZOLE 3 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN versus M ZOLE 3 COMBINATION PACK.
DIFLUCAN vs M-ZOLE 3 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) is a triazole antifungal agent that inhibits fungal cytochrome P450 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Miconazole inhibits fungal CYP450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity. Zinc pyrithione inhibits fungal growth by disrupting membrane transport and inhibiting energy metabolism.
Oral or IV: 200-400 mg loading dose, then 100-200 mg once daily. Dose and duration depend on indication.
A single oral dose of 3 tablets (M-ZOLE 3 COMBINATION PACK) as a one-time treatment.
None Documented
None Documented
30 hours (range 20-50 hours); prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min)
Terminal elimination half-life 20-30 hours in healthy adults; prolonged in renal impairment (up to 40-50 hours) and hepatic impairment
Renal: 80% unchanged; fecal/biliary: 11% as metabolites
Renal: ~70-80% as unchanged drug and metabolites; biliary/fecal: ~20%
Category C
Category C
Antifungal
Antifungal